







# Multidimensional characterization of erectile dysfunction in young man living with HIV: a cross-sectional study

G. Tiecco1, M. Di Gregorio1, C. Colangelo1, P. Facondo2, A. Delbarba2, C. Cappelli2, S. Storti1, M. Salvi1, M. Alberti1, E. Focà1, F. Castelli1, E. Quiros-Roldan1

1 Department of Clinical and Experimental Sciences, SD of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy

2 Department of Clinical and Experimental Sciences, SSD of Endocrinology and Metabolism, University of Brescia and ASST Spedali Civili di Brescia, 25123 Brescia, Italy

### Introduction

- Erectile dysfunction (ED) is a prevalent concern among young men living with HIV (yMLWH) [1,2].
- We conducted a cross-sectional study to comprehensively characterize ED in yMLWH, considering metabolic, hormonal, vascular, and psychological factors.

#### **Methods**

- This is a monocentric cross-sectional study in which we enrolled yMLWH attending our Unit of Infectious Diseases in Brescia.
- Inclusion criteria were a HIV-infection and age between 18 and 50 years old.
- All yMLWH from June 2023 to December 2023 were asked for symptoms of ED during the routinary follow up visits.
- In case of referred ED, the severity and its psychological aspects were assessed using the International Index of Erectile Function-5 (IIEF-5) and the Structured Interview on Erectile Dysfunction (SIEDY) [3].
- Metabolic and hormonal assays were performed, and the Score2 was used to assess the cardiovascular risk.
- Additionally, a dynamic penile color-doppler echography (dpCDE) performed by an Endocrinology and Andrology Specialist was employed to evaluate functional and structural vascular issues contributing to ED.

# **Results**

- In the study period, 310 yMLWH were assessed for eligibility, 50 (50/310, 16.1%) reported ED and were enrolled with a median age of 45.5 (range 29-50) years old, a median Body Mass Index of 25.5 (range 17.7-39.1), and a median Score2 of 2.5% (range 1%-5.5%).
- Comorbidities were absent in 32 (64%) yMLWH, while 8 (16%) and 9 (18%) were receiving treatment for arterial hypertension and dyslipidemia, respectively.
- All yMLWH were virologically suppressed with a median CD4/CD8 ratio of 0.75 (range 0.27-2.23).
- Twenty-four (48%) taking a dolutegravirbased dual regimen.

- According to the IIEF-5, severe ED was observed in 14 yMLWH (28%), while 35 (70%) were identified with a psychological etiology for their ED based on the SIEDY scale 3.
- As regards dpCDE, 17 (34%) yMLWH exhibit a suboptimal/delayed R-ICI (response to intracavernous injection).
- Evaluation of penile artery flow indicated that 15 (30%) yMLWH had frankly pathological peak systolic velocity (PSV) values bilaterally or unilaterally, reaching 28 (46%) with agerelated PSV pathological scores.
- As regards structural vascular abnormalities, 43 (86%) yMLWH exhibit elevated intimamedia thickness (IMT) bilaterally or unilaterally, and 30 (60%) display at least one significant arterial anastomosis that could contribute to erectile potency reduction.

## Conclusion

- ED in YMLWH has a multifactorial etiology
- No ED was solely explained based on hormonal levels, rather, substantial functional or structural vascular alterations were observed in nearly all enrolled yMLWH.
- Clinicians should recognize that relying solely on validated questionnaires to assess erectile dysfunction in yMLWH may obscure early signs of vascular impairment.
- Given the potential predictive value of ED for major cardiovascular events within specific populations, all yMLWH were instructed to undergo a carotid artery echocardiogram and treadmill test.

Figure 1 Demographic features and comorbidities of the included yMLWH				
Demographic				
>	Age (years), median (range)		45.5 (29-50)	
>	BMI (Kg/m2), median (range)		25.5 (17.7-39.1)	
>	PAS (mmHg), median (range)		120 (95-160)	
>	PAD (mmHg), median (range)		80 (60-105)	
>	IIEF-5 score, median (range)		15 (5-25)	
Comorbidities				
>	Hypertension, n (%)		10 (20)	
>	Previous cardiovascular events, n (%)		2 (4)	
>	Neuro-pelvic disease, n (%)		4 (8)	
>	Diabetes, n (%)		4 (8)	
>	Familiarity for cardiovascular events, n (%)		4 (8)	
>	IRC, n (%)		2 (4)	
>	Rheumatoid arthritis, n (%)		1 (2)	
>	Psychiatric diseases, n (%)		8 (16)	
>	Anti-hypertensive therapy, n (%)		8 (16)	
	Hypocholoctorolomic agents in (%)		0 /10)	
Figure 2 Dynamic penile color-doppler echography (dpCDE)				
Dynamic markers				
>	Drug response, median (range)	60% (40-90)		
>	Peak systolic velocity (left), median (range)	49.5 cm/s (18-100)		
>	Peak systolic velocity (right), median (range)	46 cm/s (12-100)		
>	End dyastolic velocity (right), median (range)	4.5 cm/s (0-12)		
>	End dyastolic velocity (left), median (range)	4.5 cm/s (0-12)		
>	Intima-media thickness (right), median (range)	0.3 mm (0-2-0.5)		
>	Intima-media thickness (left), median (range)	0.3 mm (0.2-0.5)		
Morphology markers				
>	Caverno-cavernous anastomosis, n (%)	14 (28)		
>	Dorsal-cavernous anastomosis, n (%)	24 (48)		
>	Accessory cavernous arteries, n (%)	5 (10)		
>	Penile plaques, n (%)	2 (4)	2 (4)	

## References

- De Vincentis S, et al. Determinants of sexual function in men living with HIV younger than 50 years old: Focus on organic, relational, and psychological issues. Andrology. 2023 Sep;11(6):954-969. De Vincentis S, et al. HIV and Sexual Dysfunction in Men. J Clin Med. 2021 Mar 5;10(5):1088.

- Corona G, et al. SIEDY scale 3, a new instrument to detect psychological component in subjects with erectile dysfunction. J Sex Med. 2012 Aug;9(8):2017-26. Smit M, et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017 Oct 23;12(10):e0186638.